Literature DB >> 8564266

Evaluation of the receptor selectivity of the H3 receptor antagonists, iodophenpropit and thioperamide: an interaction with the 5-HT3 receptor revealed.

R Leurs1, M T Tulp, W M Menge, M J Adolfs, O P Zuiderveld, H Timmerman.   

Abstract

1. In the present study we evaluated the receptor selectivity of the potent histamine H3 receptor antagonist, iodophenpropit (IPP) in comparison with the prototype antagonist, thioperamide. 2. IPP proved to be a potent competitive H3 receptor antagonist as measured against (R)-alpha-methylhistamine-induced inhibition of electrically-evoked contractions of the guinea-pig jejunum (pA2 = 9.12 +/- 0.06, Schild slope: 1.0 +/- 0.1, n = 8). In the same assay, thioperamide was slightly less potent (pA2 = 8.9 +/- 0.2). 3. In radioligand binding studies, IPP showed a high affinity for the H3 receptor. Displacement of [125I]-IPP binding to rat cortex membranes by unlabelled IPP resulted in a Ki value of 0.97 +/- 0.06 nM (n = 3). In contrast, IPP showed only a weak affinity for the histamine H1- and H2 receptor. Displacement of [3H]-mepyramine and [125I]-iodoaminopotentidine binding to respectively guinea-pig H1- and human H2 receptors by IPP resulted in Ki values of 1.71 +/- 0.32 microM (n = 3) and 2.28 +/- 0.81 microM (n = 3). For thioperamide the affinities for the H1-, H2- and H3 receptor were respectively > 10 microM, > 10 microM and 4.3 +/- 1.6 nM (n = 7). 4. Testing IPP and thioperamide in 39 different receptor binding assays revealed that IPP showed relatively high affinity for the 5-hydroxytryptamine 5-HT3 receptor (Ki = 11 +/- 1 nM, n = 3), the alpha 2-adrenoceptor (Ki = 120 +/- 5 nM, n = 3) and the sigma receptor (Ki = 170 +/- 70 nM, n = 3). Thioperamide showed relatively high affinity for the 5-HT3 receptor (Ki = 120 +/- 30 nM, n = 3) and the sigma receptor (Ki = 180 +/- 90 nM, n = 3). 5. Due to the low density of histamine H3 receptors in the brain, the interaction of IPP with the 5-HT3-, the alpha 2- and the sigma receptor might interfere with [125I]-IPP binding to rat cortex membranes. Yet, in this preparation [125I]-IPP binding was not influenced by ondansetron, yohimbine or haloperidol. The interaction with the 5-HT3 receptor was not restricted to IPP or thioperamide, but was alsofound with other H3 receptor antagonists. The potent H3 receptor agonist imetit, a compound belongingto the same chemical class of IPP, also interacted with the 5-HT3 receptor (Ki = 240 +/- 40 nM). In contrast,histamine or the H3 receptor agonist, (R)-a-methylhistamine showed no affinity for the 5-HT3 receptor.7 In the guinea-pig isolated ileum, imetit evoked concentration-dependent contractions, resulting in apD2 value of 4.72 +/- 0.03 (n = 9). The contractions were antagonized by ondansetron, yielding a pA2 valueof 7.1 +/- 0.1 (n = 9). Similarly ondansetron antagonized the contractions evoked by the 5-HT3 receptoragonist, 2-methyl-5-HT with a pA2 value of 7.3 +/- 0.1 (n = 4). IPP and thioperamide did not mimic 2-methyl-5-HT but non-competitively inhibited the 2-methyl-5-HT-induced contractions of thispreparation.8 In an in vivo model for 5-HT3 activity, the Von Bezold Jarisch reflex, thioperamide showedantagonism in low dosages, which correlated well with the affinity for the 5-HT3 receptor site. Yet, athigher dosages no further 5-HT3 receptor antagonism was observed. For IPP no 5-HT3 receptor activitycould be observed in vivo.9 In the present study we showed that many H3 receptor compounds, that are regarded as highlyselective (including the prototype drug, thioperamide), also interact with the 5-HT3 receptor, albeit athigher drug concentrations.Keywords.: Histamine H3-receptor; iodophenpropit; thioperamide; receptor selectivity; 5-hydroxytryptamine 5-HT3 receptor;guinea-pig intestine; rat brain; Von Bezold Jarisch reflex

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8564266      PMCID: PMC1908963          DOI: 10.1111/j.1476-5381.1995.tb15071.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  18 in total

Review 1.  The histamine H3-receptor: a target for developing new drugs.

Authors:  R Leurs; H Timmerman
Journal:  Prog Drug Res       Date:  1992

2.  A simple and rapid in vitro test system for the screening of histamine H3 ligands.

Authors:  R C Vollinga; O P Zuiderveld; H Scheerens; A Bast; H Timmerman
Journal:  Methods Find Exp Clin Pharmacol       Date:  1992-12

Review 3.  5-HT3 receptors.

Authors:  G J Kilpatrick; K T Bunce; M B Tyers
Journal:  Med Res Rev       Date:  1990 Oct-Dec       Impact factor: 12.944

Review 4.  Histaminergic transmission in the mammalian brain.

Authors:  J C Schwartz; J M Arrang; M Garbarg; H Pollard; M Ruat
Journal:  Physiol Rev       Date:  1991-01       Impact factor: 37.312

5.  Guinea pig histamine H1 receptor. I. Gene cloning, characterization, and tissue expression revealed by in situ hybridization.

Authors:  E Traiffort; R Leurs; J M Arrang; J Tardivel-Lacombe; J Diaz; J C Schwartz; M Ruat
Journal:  J Neurochem       Date:  1994-02       Impact factor: 5.372

6.  The first radiolabeled histamine H3 receptor antagonist, [125I]iodophenpropit: saturable and reversible binding to rat cortex membranes.

Authors:  F P Jansen; B Rademaker; A Bast; H Timmerman
Journal:  Eur J Pharmacol       Date:  1992-07-07       Impact factor: 4.432

7.  S-[2-(4-imidazolyl)ethyl]isothiourea, a highly specific and potent histamine H3 receptor agonist.

Authors:  M Garbarg; J M Arrang; A Rouleau; X Ligneau; M D Tuong; J C Schwartz; C R Ganellin
Journal:  J Pharmacol Exp Ther       Date:  1992-10       Impact factor: 4.030

8.  Identification of endothelial H1, vascular H2 and cardiac presynaptic H3 receptors in the pithed rat.

Authors:  B Malinowska; E Schlicker
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-01       Impact factor: 3.000

9.  Histamine H2-receptor agonists. Synthesis, in vitro pharmacology, and qualitative structure-activity relationships of substituted 4- and 5-(2-aminoethyl)thiazoles.

Authors:  J C Eriks; H van der Goot; G J Sterk; H Timmerman
Journal:  J Med Chem       Date:  1992-08-21       Impact factor: 7.446

10.  Development of high-affinity 5-HT3 receptor antagonists. Structure-affinity relationships of novel 1,7-annelated indole derivatives.

Authors:  I van Wijngaarden; D Hamminga; R van Hes; P J Standaar; J Tipker; M T Tulp; F Mol; B Olivier; A de Jonge
Journal:  J Med Chem       Date:  1993-11-12       Impact factor: 7.446

View more
  9 in total

1.  Detection of multiple H3 receptor affinity states utilizing [3H]A-349821, a novel, selective, non-imidazole histamine H3 receptor inverse agonist radioligand.

Authors:  David G Witte; Betty Bei Yao; Thomas R Miller; Tracy L Carr; Steven Cassar; Rahul Sharma; Ramin Faghih; Bruce W Surber; Timothy A Esbenshade; Arthur A Hancock; Kathleen M Krueger
Journal:  Br J Pharmacol       Date:  2006-05-22       Impact factor: 8.739

2.  Histamine H(3) receptor-mediated inhibition of depolarization-induced, dopamine D(1) receptor-dependent release of [(3)H]-gamma-aminobutryic acid from rat striatal slices.

Authors:  J A Arias-Montaño; B Floran; M Garcia; J Aceves; J M Young
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

3.  Targeted disruption of H3 receptors results in changes in brain histamine tone leading to an obese phenotype.

Authors:  Kazuhiko Takahashi; Hiroaki Suwa; Tomoo Ishikawa; Hidehito Kotani
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

4.  Characterization of the binding of [3H]-clobenpropit to histamine H3-receptors in guinea-pig cerebral cortex membranes.

Authors:  E A Harper; N P Shankley; J W Black
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

5.  Samelisant (SUVN-G3031), a potent, selective and orally active histamine H3 receptor inverse agonist for the potential treatment of narcolepsy: pharmacological and neurochemical characterisation.

Authors:  Ramakrishna Nirogi; Vijay Benade; Saivishal Daripelli; Ramkumar Subramanian; Venkatesh Kamuju; Gopinadh Bhyrapuneni; Nageswara Rao Muddana; Venkat Reddy Mekala; Surendra Petlu; Pradeep Jayarajan; Rajesh Badange; Anil Shinde; Venkat Jasti
Journal:  Psychopharmacology (Berl)       Date:  2021-02-07       Impact factor: 4.530

6.  [3H]-thioperamide as a radioligand for the histamine H3 receptor in rat cerebral cortex.

Authors:  A Alves-Rodrigues; R Leurs; T S Wu; G D Prell; C Foged; H Timmerman
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

7.  Implementation of a fluorescence-based screening assay identifies histamine H3 receptor antagonists clobenpropit and iodophenpropit as subunit-selective N-methyl-D-aspartate receptor antagonists.

Authors:  Kasper B Hansen; Praseeda Mullasseril; Sara Dawit; Natalie L Kurtkaya; Hongjie Yuan; Katie M Vance; Anna G Orr; Trine Kvist; Kevin K Ogden; Phuong Le; Kimberly M Vellano; Iestyn Lewis; Serdar Kurtkaya; Yuhong Du; Min Qui; T J Murphy; James P Snyder; Hans Bräuner-Osborne; Stephen F Traynelis
Journal:  J Pharmacol Exp Ther       Date:  2010-03-02       Impact factor: 4.030

Review 8.  International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors.

Authors:  Pertti Panula; Paul L Chazot; Marlon Cowart; Ralf Gutzmer; Rob Leurs; Wai L S Liu; Holger Stark; Robin L Thurmond; Helmut L Haas
Journal:  Pharmacol Rev       Date:  2015-07       Impact factor: 25.468

Review 9.  Histamine, histamine receptors, and neuropathic pain relief.

Authors:  Ilona Obara; Vsevolod Telezhkin; Ibrahim Alrashdi; Paul L Chazot
Journal:  Br J Pharmacol       Date:  2019-06-07       Impact factor: 8.739

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.